SK7682003A3 - GABA enhancers in the treatment of diseases relating to reduced neurosteroid activity - Google Patents

GABA enhancers in the treatment of diseases relating to reduced neurosteroid activity Download PDF

Info

Publication number: SK7682003A3
Authority: SK; Slovakia
Prior art keywords: gaba; neurosteroid; compound; disorder; disease
Prior art date: 2000-11-20

Application number

SK768-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Bjarke Ebert

Andersen Peter Hongaard

Original Assignee

Lundbeck & Co As H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-20

Filing date

2001-11-20

Publication date

2003-10-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8159857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK7682003(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-11-20 Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

2003-10-07 Publication of SK7682003A3 publication Critical patent/SK7682003A3/sk

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 35
230000000694 effects Effects 0.000 title claims abstract description 18
230000002829 reductive effect Effects 0.000 title claims abstract description 8
239000003623 enhancer Substances 0.000 title claims abstract description 7
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 title claims description 24
229960003692 gamma aminobutyric acid Drugs 0.000 title claims description 22
201000010099 disease Diseases 0.000 title claims description 15
208000035475 disorder Diseases 0.000 claims abstract description 20
239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 claims abstract description 7
230000003371 gabaergic effect Effects 0.000 claims abstract description 7
150000001875 compounds Chemical class 0.000 claims description 34
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 30
239000000186 progesterone Substances 0.000 claims description 15
229960003387 progesterone Drugs 0.000 claims description 15
ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 claims description 12
230000003637 steroidlike Effects 0.000 claims description 11
201000009916 Postpartum depression Diseases 0.000 claims description 10
210000004556 brain Anatomy 0.000 claims description 8
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 6
230000004913 activation Effects 0.000 claims description 6
239000003112 inhibitor Substances 0.000 claims description 6
ZJQHPWUVQPJPQT-UHFFFAOYSA-N muscimol Chemical compound NCC1=CC(=O)NO1 ZJQHPWUVQPJPQT-UHFFFAOYSA-N 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 5
230000001544 dysphoric effect Effects 0.000 claims description 4
PRJKNHOMHKJCEJ-UHFFFAOYSA-N imidazol-4-ylacetic acid Chemical compound OC(=O)CC1=CN=CN1 PRJKNHOMHKJCEJ-UHFFFAOYSA-N 0.000 claims description 4
150000003146 progesterones Chemical class 0.000 claims description 4
238000010521 absorption reaction Methods 0.000 claims description 3
230000003281 allosteric effect Effects 0.000 claims description 3
229960002870 gabapentin Drugs 0.000 claims description 3
230000009467 reduction Effects 0.000 claims description 3
PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 claims description 3
229960001918 tiagabine Drugs 0.000 claims description 3
229950004346 gaboxadol Drugs 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
230000000737 periodic effect Effects 0.000 claims 1
102000005915 GABA Receptors Human genes 0.000 abstract description 5
108010005551 GABA Receptors Proteins 0.000 abstract description 5
229940091860 GABA uptake inhibitor Drugs 0.000 abstract description 2
239000002843 gaba uptake inhibitor Substances 0.000 abstract description 2
-1 steroid compound Chemical class 0.000 abstract 2
108020003175 receptors Proteins 0.000 description 17
102000005962 receptors Human genes 0.000 description 17
241001465754 Metazoa Species 0.000 description 9
206010036618 Premenstrual syndrome Diseases 0.000 description 9
229940049706 benzodiazepine Drugs 0.000 description 9
238000012360 testing method Methods 0.000 description 8
208000027030 Premenstrual dysphoric disease Diseases 0.000 description 6
230000037396 body weight Effects 0.000 description 6
239000002775 capsule Substances 0.000 description 6
229940088597 hormone Drugs 0.000 description 6
239000005556 hormone Substances 0.000 description 6
239000007943 implant Substances 0.000 description 6
239000004480 active ingredient Substances 0.000 description 5
150000001557 benzodiazepines Chemical class 0.000 description 5
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
241000700159 Rattus Species 0.000 description 4
239000000556 agonist Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
230000005906 menstruation Effects 0.000 description 4
239000002207 metabolite Substances 0.000 description 4
239000002858 neurotransmitter agent Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
239000003826 tablet Substances 0.000 description 4
102000027484 GABAA receptors Human genes 0.000 description 3
108091008681 GABAA receptors Proteins 0.000 description 3
239000000654 additive Substances 0.000 description 3
230000007717 exclusion Effects 0.000 description 3
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000000243 solution Substances 0.000 description 3
206010002091 Anaesthesia Diseases 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
206010010904 Convulsion Diseases 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000000853 adhesive Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
206010015037 epilepsy Diseases 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
229960003132 halothane Drugs 0.000 description 2
230000000971 hippocampal effect Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
239000008101 lactose Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
238000000034 method Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000027758 ovulation cycle Effects 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
230000000542 thalamic effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
AELCINSCMGFISI-DTWKUNHWSA-N (1R,2S)-tranylcypromine Chemical compound N[C@@H]1C[C@H]1C1=CC=CC=C1 AELCINSCMGFISI-DTWKUNHWSA-N 0.000 description 1
OUENRUZPZZFMCA-YFKPBYRVSA-N 2-[(3s)-pyrrolidin-1-ium-3-yl]acetate Chemical compound OC(=O)C[C@@H]1CCNC1 OUENRUZPZZFMCA-YFKPBYRVSA-N 0.000 description 1
DUHUCHOQIDJXAT-OLVMNOGESA-N 3-hydroxy-(3-α,5-α)-Pregnane-11,20-dione Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O DUHUCHOQIDJXAT-OLVMNOGESA-N 0.000 description 1
206010001497 Agitation Diseases 0.000 description 1
KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
AOAFGVWKONLQRN-OQKWZONESA-N Cc1cc(Cl)cc(\C(=N\CCCC(N)=O)c2ccc(Cl)cc2)c1O Chemical compound Cc1cc(Cl)cc(\C(=N\CCCC(N)=O)c2ccc(Cl)cc2)c1O AOAFGVWKONLQRN-OQKWZONESA-N 0.000 description 1
108010062745 Chloride Channels Proteins 0.000 description 1
102000011045 Chloride Channels Human genes 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
206010011953 Decreased activity Diseases 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
230000009508 GABAergic inhibition Effects 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
108090000862 Ion Channels Proteins 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
206010027603 Migraine headaches Diseases 0.000 description 1
229920000715 Mucilage Polymers 0.000 description 1
229920002274 Nalgene Polymers 0.000 description 1
108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
229960003305 alfaxalone Drugs 0.000 description 1
230000009042 allosteric modification Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
229940005530 anxiolytics Drugs 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
229960000794 baclofen Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
ZGLIFVFRIOKQLE-LVZFUZTISA-N chembl2104573 Chemical compound C=1C(Cl)=CC=C(O)C=1C(=N/CCCC)/C1=CC=CC=C1Cl ZGLIFVFRIOKQLE-LVZFUZTISA-N 0.000 description 1
230000002060 circadian Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000001447 compensatory effect Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
108700023159 delta Opioid Receptors Proteins 0.000 description 1
102000048124 delta Opioid Receptors Human genes 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003596 drug target Substances 0.000 description 1
230000001037 epileptic effect Effects 0.000 description 1
230000001158 estrous effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229950004395 fengabine Drugs 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
239000003326 hypnotic agent Substances 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000006742 locomotor activity Effects 0.000 description 1
229960004391 lorazepam Drugs 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000002175 menstrual effect Effects 0.000 description 1
238000007431 microscopic evaluation Methods 0.000 description 1
230000036651 mood Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
230000036407 pain Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229960004122 phenibut Drugs 0.000 description 1
SRPNQDXRVRCTNK-UHFFFAOYSA-N pivagabine Chemical compound CC(C)(C)C(=O)NCCCC(O)=O SRPNQDXRVRCTNK-UHFFFAOYSA-N 0.000 description 1
229960003084 pivagabine Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
IBALRBWGSVJPAP-HEHNFIMWSA-N progabide Chemical compound C=1C(F)=CC=C(O)C=1C(=N/CCCC(=O)N)/C1=CC=C(Cl)C=C1 IBALRBWGSVJPAP-HEHNFIMWSA-N 0.000 description 1
229960002752 progabide Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000003044 randomized block design Methods 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
229920000260 silastic Polymers 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000012353 t test Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229950000583 tolgabide Drugs 0.000 description 1
230000007704 transition Effects 0.000 description 1
229960005318 vigabatrin Drugs 0.000 description 1
PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 1
229960002911 zonisamide Drugs 0.000 description 1
UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)
Hydrogenated Pyridines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Indole Compounds (AREA)

SK768-2003A 2000-11-20 2001-11-20 GABA enhancers in the treatment of diseases relating to reduced neurosteroid activity SK7682003A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA200001743		2000-11-20
PCT/DK2001/000773 WO2002040009A1 (en)	2000-11-20	2001-11-20	Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity

Publications (1)

Publication Number	Publication Date
SK7682003A3 true SK7682003A3 (en)	2003-10-07

Family

ID=8159857

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK768-2003A SK7682003A3 (en)	2000-11-20	2001-11-20	GABA enhancers in the treatment of diseases relating to reduced neurosteroid activity

Country Status (33)

Country	Link
US (2)	US20040024038A1 (uk)
EP (1)	EP1337247B1 (uk)
JP (1)	JP4152186B2 (uk)
KR (1)	KR100865651B1 (uk)
CN (1)	CN1318027C (uk)
AR (1)	AR031473A1 (uk)
AT (1)	ATE336242T1 (uk)
AU (2)	AU2351402A (uk)
BG (1)	BG107909A (uk)
BR (1)	BR0115668A (uk)
CA (1)	CA2429220C (uk)
CY (1)	CY1106209T1 (uk)
CZ (1)	CZ20031383A3 (uk)
DE (1)	DE60122368T2 (uk)
DK (1)	DK1337247T3 (uk)
EA (1)	EA007287B1 (uk)
ES (1)	ES2266308T3 (uk)
HR (1)	HRP20030404A2 (uk)
HU (1)	HUP0400505A3 (uk)
IL (1)	IL155587A0 (uk)
IS (1)	IS2427B (uk)
ME (1)	MEP6408A (uk)
MX (1)	MXPA03004349A (uk)
NO (1)	NO20032271L (uk)
NZ (1)	NZ525520A (uk)
PL (1)	PL361051A1 (uk)
PT (1)	PT1337247E (uk)
SI (1)	SI1337247T1 (uk)
SK (1)	SK7682003A3 (uk)
UA (1)	UA77403C2 (uk)
WO (1)	WO2002040009A1 (uk)
YU (1)	YU39003A (uk)
ZA (1)	ZA200303289B (uk)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8048917B2 (en)	2005-04-06	2011-11-01	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
CN1615146A (zh) *	2001-11-26	2005-05-11	芬策尔贝格有限两合公司	生姜提取物制剂
EP1641456B1 (en) *	2003-06-25	2010-03-03	H. Lundbeck A/S	Gaboxadol for treating depression and other affective disorders
GB0402118D0 (en)	2004-01-30	2004-03-03	Merck Sharp & Dohme	Polymorphic forms of a GABAA agonist
AU2004324938A1 (en) *	2004-06-29	2006-05-26	H. Lundbeck A/S	Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis
WO2006012563A2 (en) *	2004-07-23	2006-02-02	The Regents Of The University Of California	Method for the treatment and diagnosis of certain psychiatric disorders related to the menstrual cycle
GB0417558D0 (en) *	2004-08-06	2004-09-08	Merck Sharp & Dohme	Novel combination therapy
EP1848420A4 (en)	2005-01-28	2008-01-23	Merck & Co Inc	POLYMORPH SHAPES OF A GABAA AGONIST
US20070122507A1 (en) *	2005-05-26	2007-05-31	Palu Afa K	Histone deacetylase and tumor necrosis factor converting enzyme inhibition
US9209995B2 (en) *	2006-12-29	2015-12-08	Prodea Systems, Inc.	Presence status notification from digital endpoint devices through a multi-services gateway device at the user premises
WO2008141112A1 (en) *	2007-05-09	2008-11-20	Cenerx Biopharma, Inc.	Methods of treating rett syndrome
CN101585862B (zh) *	2008-05-20	2014-12-17	梅克芳股份公司	甾族化合物
CN103547240B (zh) *	2011-06-16	2016-03-30	索雷斯生命科学公司	用于人类自主神经系统的平衡和维持健康的系统和方法
RU2496496C1 (ru) *	2012-10-04	2013-10-27	Исаак Григорьевич Гитлин	Фармацевтическая композиция, обладающая гамк-ергической активностью
KR20240160666A (ko)	2015-07-17	2024-11-11	오비드 테라퓨틱스 인크.	가복사돌로 발달장애들을 치료하는 방법들
EP4233861A3 (en) *	2016-08-11	2023-10-11	Ovid Therapeutics, Inc.	Compositions for treatment of essential tremor
US20180338959A1 (en) *	2017-05-24	2018-11-29	Ovid Therapeutics Inc.	Treatment of depressive disorders
US12459965B2 (en)	2017-10-09	2025-11-04	Compass Pathfinder Limited	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en)	2017-10-09	2020-05-27	Compass Pathways Ltd	Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR102049522B1 (ko) *	2018-06-05	2019-11-27	충남대학교산학협력단	Gaba를 유효성분으로 하는 살모넬라 감염질환의 예방 및 치료용 조성물
KR102049526B1 (ko) *	2018-06-05	2019-11-27	충남대학교산학협력단	Gaba를 유효성분으로 하는 항결핵 약학 조성물
AU2019345312A1 (en)	2018-09-20	2021-03-25	Ovid Therapeutics Inc.	Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
WO2020106927A1 (en)	2018-11-21	2020-05-28	Certego Therapeutics	Gaboxadol for reducing risk of suicide and rapid relief of depression
CN113423399A (zh)	2018-12-17	2021-09-21	奥维德医疗公司	加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
JP2022529781A (ja)	2019-04-17	2022-06-24	コンパスパスファインダーリミテッド	サイロシビンによるうつ病及び他の様々な障害の治療
WO2021127308A1 (en)	2019-12-18	2021-06-24	Ovid Therapeutics Inc.	GABOXADOL FOR THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME
MX2022014599A (es)	2020-05-20	2022-12-16	Certego Therapeutics Inc	Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
CN114404437A (zh) *	2022-03-15	2022-04-29	山东中医药大学	没食子酰芍药苷在制备gabaa受体抑制剂中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4362731A (en) *	1980-09-01	1982-12-07	Sandoz Ltd.	Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US5120723A (en) *	1987-08-25	1992-06-09	University Of Southern California	Method, compositions, and compounds for modulating brain excitability
JPH06510999A (ja) *	1991-09-13	1994-12-08	コセンシス・インコーポレイテッド	ステロイド結合部位を有する新規ＧＡＢＡ↓ａレセプター
US5206415A (en) *	1991-12-20	1993-04-27	Washington University	Tricyclic steroid analogs
CZ300694A3 (en) *	1993-12-02	1996-05-15	Akzo Nobel Nv	Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
AP653A (en) *	1994-11-23	1998-07-21	Cocensys Inc	Androstane and pregnane series for allosteric modulations of gaba receptor.
US5776959A (en) *	1995-06-05	1998-07-07	Washington University	Anticonvulsant and anxiolytic lactam and thiolactam derivatives
EP1288220A3 (en) *	1995-06-06	2004-07-21	Euro-Celtique	Neuroactive 3.alpha.-hydroxy-steroids of the androstane and pregnane series
IT1290003B1 (it) *	1997-03-03	1998-10-19	Angelini Ricerche Spa	Uso di pivagabina per preparare composizioni farmaceutiche
GB9801208D0 (en) *	1998-01-21	1998-03-18	Merck Sharp & Dohme	Therapeutic agents
KR100599142B1 (ko) *	1998-07-22	2006-07-12	악조 노벨 엔.브이.	α- 아미노산 페닐 에스테르 유도체
AU1808401A (en) *	1999-12-08	2001-06-18	Warner-Lambert Company	Method for the stereoselective synthesis of cyclic amino acids

2001
- 2001-11-16 AR ARP010105378A patent/AR031473A1/es unknown
- 2001-11-20 AU AU2351402A patent/AU2351402A/xx active Pending
- 2001-11-20 DK DK01996378T patent/DK1337247T3/da active
- 2001-11-20 WO PCT/DK2001/000773 patent/WO2002040009A1/en not_active Ceased
- 2001-11-20 BR BR0115668-3A patent/BR0115668A/pt not_active Application Discontinuation
- 2001-11-20 KR KR1020037006754A patent/KR100865651B1/ko not_active Expired - Fee Related
- 2001-11-20 NZ NZ525520A patent/NZ525520A/en unknown
- 2001-11-20 AU AU2002223514A patent/AU2002223514B2/en not_active Ceased
- 2001-11-20 UA UA2003054188A patent/UA77403C2/uk unknown
- 2001-11-20 DE DE60122368T patent/DE60122368T2/de not_active Expired - Lifetime
- 2001-11-20 HU HU0400505A patent/HUP0400505A3/hu unknown
- 2001-11-20 SK SK768-2003A patent/SK7682003A3/sk not_active Application Discontinuation
- 2001-11-20 MX MXPA03004349A patent/MXPA03004349A/es active IP Right Grant
- 2001-11-20 YU YU39003A patent/YU39003A/sh unknown
- 2001-11-20 ME MEP-64/08A patent/MEP6408A/xx unknown
- 2001-11-20 EA EA200300594A patent/EA007287B1/ru not_active IP Right Cessation
- 2001-11-20 CZ CZ20031383A patent/CZ20031383A3/cs unknown
- 2001-11-20 PL PL36105101A patent/PL361051A1/xx unknown
- 2001-11-20 HR HR20030404A patent/HRP20030404A2/hr not_active Application Discontinuation
- 2001-11-20 EP EP01996378A patent/EP1337247B1/en not_active Expired - Lifetime
- 2001-11-20 CN CNB018190936A patent/CN1318027C/zh not_active Expired - Fee Related
- 2001-11-20 JP JP2002542383A patent/JP4152186B2/ja not_active Expired - Fee Related
- 2001-11-20 CA CA002429220A patent/CA2429220C/en not_active Expired - Fee Related
- 2001-11-20 SI SI200130619T patent/SI1337247T1/sl unknown
- 2001-11-20 AT AT01996378T patent/ATE336242T1/de active
- 2001-11-20 PT PT01996378T patent/PT1337247E/pt unknown
- 2001-11-20 IL IL15558701A patent/IL155587A0/xx unknown
- 2001-11-20 ES ES01996378T patent/ES2266308T3/es not_active Expired - Lifetime
2003
- 2003-04-29 ZA ZA2003/03289A patent/ZA200303289B/en unknown
- 2003-04-30 IS IS6803A patent/IS2427B/is unknown
- 2003-05-01 US US10/430,704 patent/US20040024038A1/en not_active Abandoned
- 2003-05-20 NO NO20032271A patent/NO20032271L/no not_active Application Discontinuation
- 2003-06-13 BG BG107909A patent/BG107909A/bg unknown
2006
- 2006-10-20 CY CY20061101505T patent/CY1106209T1/el unknown
2008
- 2008-06-27 US US12/163,883 patent/US20090143435A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CY1106209T1 (el)	2011-06-08
US20090143435A1 (en)	2009-06-04
AU2002223514B2 (en)	2006-11-30
PL361051A1 (en)	2004-09-20
IS6803A (is)	2003-04-30
EA200300594A1 (ru)	2003-10-30
AU2351402A (en)	2002-05-27
PT1337247E (pt)	2006-11-30
MEP6408A (xx)	2010-02-10
MXPA03004349A (es)	2003-08-19
EP1337247A1 (en)	2003-08-27
ES2266308T3 (es)	2007-03-01
CN1318027C (zh)	2007-05-30
ZA200303289B (en)	2005-07-27
CZ20031383A3 (cs)	2003-08-13
NO20032271D0 (no)	2003-05-20
SI1337247T1 (sl)	2006-12-31
US20040024038A1 (en)	2004-02-05
IL155587A0 (en)	2003-11-23
ATE336242T1 (de)	2006-09-15
IS2427B (is)	2008-10-15
BR0115668A (pt)	2003-09-02
DE60122368T2 (de)	2007-08-09
KR100865651B1 (ko)	2008-10-29
HUP0400505A3 (en)	2008-08-28
HK1075010A1 (en)	2005-12-02
CN1592616A (zh)	2005-03-09
DE60122368D1 (de)	2006-09-28
WO2002040009A1 (en)	2002-05-23
YU39003A (sh)	2006-05-25
AR031473A1 (es)	2003-09-24
EP1337247B1 (en)	2006-08-16
BG107909A (bg)	2004-08-31
JP2004513921A (ja)	2004-05-13
NZ525520A (en)	2005-04-29
CA2429220C (en)	2009-09-15
CA2429220A1 (en)	2002-05-23
HRP20030404A2 (en)	2005-04-30
NO20032271L (no)	2003-05-20
DK1337247T3 (da)	2006-12-04
JP4152186B2 (ja)	2008-09-17
HUP0400505A2 (hu)	2004-07-28
KR20030065517A (ko)	2003-08-06
EA007287B1 (ru)	2006-08-25
UA77403C2 (en)	2006-12-15

Legal Events

Date	Code	Title	Description
2010-05-07	FC9A	Refused patent application

Publication	Publication Date	Title
CA2429220C (en)	2009-09-15	Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity
AU2002223514A1 (en)	2002-08-01	Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity
EP1839657A2 (en)	2007-10-03	A method for treating vascular headaches
AU2013258566B2 (en)	2017-03-16	Pyrazole derivative and use thereof for medical purposes
JPH11509844A5 (uk)	2009-05-07
JP2005527599A (ja)	2005-09-15	肥満および摂食障害におけるゾニサミドの使用
JPH11509844A (ja)	1999-08-31	プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制
EP1244456A1 (en)	2002-10-02	A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
BRPI0810525B1 (pt)	2021-05-11	Uso de pioglitazona ou rosiglitazona pra tratar a dependência em álcool, cocaína e nicotina, composições farmacêuticas e formas de dosagem, e combinações farmacêuticas contendo pioglitazona ou rosiglitazona
KR20040030788A (ko)	2004-04-09	요실금 치료를 위한 아릴(또는 헤테로아릴)아졸릴카르비놀 유도체
Hamann et al.	2002	Effects of striatal injections of GABAA receptor agonists and antagonists in a genetic animal model of paroxysmal dystonia
JP2002508322A (ja)	2002-03-19	男性における低アンドロゲン対エストロゲン比及び排尿筋−括約筋筋失調の治療におけるアロマターゼ阻害剤の利用、及びオス齧歯類における協調運動障害を試験する方法
MXPA01012794A (es)	2002-09-02	Composicion farmaceutica para la terapia de sintomas del tracto urinario inferior.
Obara et al.	2019	Effects of distigmine on the mechanical activity of urinary bladder smooth muscle
HK1075010B (en)	2008-01-25	Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity
Sakono et al.	2025	Inhibitory effects of a κ-opioid receptor agonist and neurokinin-3 receptor antagonist on testosterone secretion in male rats
WO1998005207A1 (en)	1998-02-12	Method for treating excessive aggression
WO2026037909A1 (en)	2026-02-19	N,n-bis-2-mercaptoethyl isophthalamide for use in the treatment of pain
JP2017197448A (ja)	2017-11-02	排尿障害治療用配合剤
WO1998038988A1 (en)	1998-09-11	Use of pivagabin to prepare pharmaceutical compositions